NEOS Investment Management LLC Purchases 53,891 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

NEOS Investment Management LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 35.5% during the fourth quarter, HoldingsChannel reports. The fund owned 205,829 shares of the biopharmaceutical company’s stock after buying an additional 53,891 shares during the quarter. NEOS Investment Management LLC’s holdings in Gilead Sciences were worth $19,012,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the business. Bellevue Group AG lifted its stake in shares of Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after buying an additional 7,093 shares in the last quarter. Quantinno Capital Management LP lifted its position in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC boosted its holdings in shares of Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after acquiring an additional 3,627 shares during the period. Capital Investment Advisors LLC grew its position in shares of Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Gilead Sciences by 3.9% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock valued at $13,132,000 after purchasing an additional 5,382 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $109.27 on Thursday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a market cap of $136.08 billion, a PE ratio of 295.32, a PEG ratio of 0.71 and a beta of 0.21. The company’s fifty day moving average is $104.69 and its 200 day moving average is $94.46. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.89%. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Analyst Ratings Changes

Several research analysts have commented on the company. Wells Fargo & Company raised their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Piper Sandler boosted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Finally, Oppenheimer boosted their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 over the last three months. 0.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.